Abstract HER-2/neu, a tumor-associated antigen (TAAg), plays a critical role in oncogenesis of various tumor types, and its selective overexpression by malignant tumor cells makes it an ideal target for immunotherapy. A prerequisite for clinical vaccines is the construction of safe and highly immunogenic reagents able to generate efficient immune responses against TAAg. Previous protein vaccines, consisting of the extracellular domain of HER-2/neu (p NeuECD ), were shown to elicit an immune response that did not provide protection from transplantable tumors expressing HER-2/neu. Here we showed that virosomes, which consist of reconstituted viral envelopes without viral genetic material, can act as a carrier and an adjuvant for a truncated protein p NeuECD . Mice vaccinated with p NeuECD either encapsulated in virosomes or bound to the virosomal membrane (Vir-p NeuECD ), generated rNeu-specific humoral and cytotoxic immune responses. In addition, Vir-p NeuECD induced significant tumor rejection and additionally did not lead to delayed tumor formation when compared with free p NeuECD in complete Freund's adjuvant. There was no difference between the virosomal constructs. Taken together these results suggest that virosomes, as clinically approved safe vaccines, can be used to elicit both humoral and cellmediated responses against TAAg and induce tumor rejection. Our model is providing important preclinical data to design human vaccination trials for patients with tumors overexpressing HER-2/neu, either as a primary vaccination or as a boost in combination with other vaccines in a context of an adjuvant treatment plan.
Introduction
HER-2/neu, a transmembrane tyrosine kinase, has been linked to the malignant transformation of human breast, prostate, lung, and colorectal tumors [1] [2] [3] [4] . HER-2/neu has become an attractive target and recognized antigen for immunotherapy, as both detectable HER-2/neu-specific IgG antibodies and cytotoxic T cell (CTL) responses have been demonstrated in patients with cancer overexpressing HER-2/neu, thus indicating that self-tolerance has been circumvented [5, 6] . A prerequisite for clinical applications of immunotherapy or cancer vaccines is the construction of highly immunogenic reagents able to efficiently generate immune responses against tumor-associated antigens (TAAgs). Replication incompetent viral vectors, developed to express TAAgs, have been demonstrated to be safe and potent in generating a humoral and cellular immune response [7, 8] . However, despite the superiority of viral vaccines there is an increasing safety concern when oncogenic DNA inserts are involved. In contrast, virosomes represent an attractive new delivery system to antigen-presenting cells (APCs) based on their unique targeting and membrane fusion properties [9] . Virosomes are reconstituted influenza viral envelopes, which lack the genetic material but retain the cell entry and membrane fusion characteristics of the virus they are derived from [10] . By virtue of this membrane fusion activity they can introduce exogenous antigens directly into the cytosols of APCs, thus accessing the MHC class I pathway without de novo protein synthesis [11] [12] [13] . In addition to facilitating the uptake of exogenous proteins, virosomes have also been shown to act as immunoadjuvants and to induce an efficient humoral and cytotoxic immune response in primed mice against viral antigens [14] .
In our study, we used virosomes as an immunoadjuvant and new antigen carrier system to investigate the immune response and tumor rejection capacity of vaccinated mice in comparison to protein and viral vaccines. We chose HER-2/neu as a model tumor antigen and used the extracellular domain of HER-2/neu protein (p NeuECD ), first to avoid the restriction of immunodominant epitopes and second to generate durable immunity by immunizing with putative T-helper epitopes. Our results showed that virosomes could be used as carrier and immunoadjuvant for a truncated p NeuECD protein encapsulated or bound to different virosomal constructs (Vir-p NeuECD ). Vir-p NeuECD protected a significant number of mice from tumor formation compared with free p NeuECD + complete Freund's adjuvant (CFA) and this protection correlated with the induction of cytotoxic and humoral immune responses. This paper supports the use of virosomes as a new and safe carrier system and adjuvant for cancer vaccines.
Material and methods

Chemicals
N-Hydroxysuccinimide ester of palmitic acid (NHSP), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium methyl sulfate (DOTAP), and 3-sn-phosphatidylcholine (PC; Sigma, St Louis, MO, USA).
Mice
Female virgin MMTV/r-Neu FVB mice (H-2q) transgenic for the rat neu protein (rNeu-TG) and FVB/N mice (H2q) were purchased from Charles River, Germany. Laboratory animal care was in accordance with institutional guidelines.
Cell lines
IT22 3T3 (H-2q) fibroblasts were cotransfected with a SV2-Neo-SP65 and a pBR322-rNeu plasmid. G418-resistent rNeu + clones (IT22-neu) were selected for their rNeu expression by indirect immunofluorescence by FACS. The syngeneic rNeu + (H-2q) breast cancer cell line NF9006 derived from a rNeu-TG mouse and the syngeneic rNeu À (H-2q) breast cancer cell line K635 derived from a c-myc-TG mouse have previously been described [15] .
Amplification and cloning of the extracellular part of HER-2/neu (Neu ECD )
The DNA sequence coding for the extracellular part of rat HER-2/neu (corresponding to amino acid 1-655) was amplified by PCR. The following primers were used: 5¢-AATTCGCAATGATCATCATGGAGCTG-3¢ (5¢ primer) and 5¢-GCCAGCCCGGTGACATAA-3¢ (3¢ primer) using pSV2neuN [16] as template. The 3¢ primer contained a stop codon, so that only the extracellular part of HER-2/neu was expressed. The fragment was cloned into pVAX1 (Invitrogen, Cat: V260-20; Groningen, Netherland), amplified, purified, and used as a vaccine, either as free DNA or packed into virosomes.
Immunohistochemistry
Cytospins of NF9006 and Vir-DNA-Neu ECD infected COS cells were incubated with a mouse anti-rat HER-2/ neu (7.16.4, Oncogene Science) Ab diluted in PBS and goat serum. After incubation with biotin-conjugated goat antimouse Ab (Dako, Copenhagen, Denmark), reactivities were detected using an avidin-biotin complex (Dako) and Newfuchsin substrate (Sigma) according to manufacturer's instructions.
Expression plasmid construction, protein expression, and isolation/purification of the p NeuECD cDNA encoding the extracellular part of rat Neu (Neu ECD ) was ligated into MCS of the pBADHisB expression vector (Invitrogen). For protein expression pBADHisB-Neu ECD was grown in Escherichia coli to an OD 600 of 0.5, protein expression was induced with L-arabinose at a final concentration of 0.2% for 3 h. Cells were then pelleted and sonicated, and p NeuECD was isolated and purified from the collected lysates by quantitative SDS PAGE with Model 491 Prep Cell (BioRad Laboratories, Glattbrugg, Switzerland) according to the manufacturer's instructions. Purified fractions were collected and analyzed in a Western blot.
Fatty acylation of the p NeuECD
To attach the antigen (p NeuECD ) to the surface of the virosomal lipid bilayer, p NeuECD was covalently coupled to palmitic acid using a fatty acylation reaction [17] .
Preparation of DNA plasmid-virosome complexes (Vir-DNA-Neu ECD )
Plasmid pVAX1-Neu ECD was encapsulated in virosomes as follows. A 1.5-ml solution of plasmid (590 lg) was added to 3 ml of HBS (Hepes, 20 mmol/l; NaCl, 150 mmol/l, pH 7.4) and mixed with 1.5 ml of HBS containing 2.95-mg DOTAP and then ultrasonicated. Furthermore, influenza virosomes containing 70% DOTAP in the lipid membrane were prepared as described previously [18] . DNA plasmid-virosome complexes were prepared by mixing DOTAP-encapsulated plasmid liposomes (6 ml) with 2.8 ml of DOTAP-virosomes, and subsequently fused by ultrasonication at room temperature. The resulting solution contained 66.2 lg plasmid/ml.
Preparation of Vir-p
NeuECD mem
Hemagglutinin (HA) from the A/Singapore/6/86 strain of influenza virus was isolated as previously described [18, 19] . Supernatant containing solubilized HA trimer (3.9 mg/ml) in 0.01 M E 12 E 8 was used for the production of virosomes. PC (112 mg) in chloroform was added to a round-bottomed flask, and the chloroform was evaporated by a rotary evaporator. The supernatant (7.1 ml containing 28 mg HA) and 11 ml of palmitoyl p NeuECD were added to the flask. The PC film was solubilized under gentle shaking. The mixture was briefly treated by ultrasonication and then filtered through a 0.2-lm filter. The domain of Neu ECD was first cloned into a vaccinia shuttle vector (generous gift from Dr K.Tsung, San Francisco, CA, USA) enabling insertion and transcription in the viral genome. The insert was flanked by two viral sequences enabling homologous recombination in the A56R loci (hemagglutinin-nonessential gene) of vaccinia virus (Copenhagen strain). A clonal recombinant virus was obtained after several rounds of plaque isolation (using transient gpt selection [20] ) on CV-1 cells (ATCC CCL70). Several separately isolated clones were PCR screened and one positive recombinant was then amplified and concentrated on 36% sucrose cushions. Viral solutions were titered on CV-1 cells. Virus replication was inactivated by a limited treatment with 1 lg/ml psoralen (Trioxsalen; Calbiochem, Cambridge, MA, USA) for 10 min at room temperature followed by 8 min exposure to 354-nm long-wave UV (Stratalinker; Stratagene, La Jolla, CA, USA) as described previously [8, 21] .
FACS analysis for Neu expression on cell line and rNeu-specific antibody levels in serum Syngeneic fibroblast cells (IT22-neu) were analyzed for their rNeu-expression as previously described [22] . RNeu + NF9006 cells (0.5·10 6 ) were used to determine rNeu-specific antibodies in sera of mice after different vaccines. The method used and cell analysis for fluorescence on a FACScan has been previously described [23] .
Vaccination protocols
Vaccination/boost studies were performed in female virgin FVB mice as previously described [15] 
CTL generation
Spleen cells (at 5·10 5 cells/well) were restimulated in vitro on irradiated IT22-neu cells seeded at 1.5·10 5 cells/ well in 24-well plates. Spleen cells were cocultured for 5 days, then used for the cytotoxicity assay described below.
XTT-based cytotoxicity assay
Lytic function of restimulated effector cells against IT22-neu and IT22 target cells was evaluated at different effector to target ratios (E/T 100:1-0.3:1) in triplicate samples. After overnight coincubation of effector and target cells, 50 ll of XTT-solution (Roche Diagnostics, Rotkreuz, Switzerland) was added to each well according to the manufacturer's instructions, and absorbance at 490 nm was evaluated on an ELISA reader (BioRad). Percentage specific lysis was calculated for each E/ T ratio as follows:
%Neu-specific killing ¼ %killing of specific targets ðIT22-neuÞ À %killing of unspecific targets ðIT22Þ
ELISA analysis of anti-p NeuECD
Anti-p NeuECD specific antibodies in the sera of mice were determined by an ELISA in flat-bottomed plates coated with p NeuECD in 50-mM carbonate buffer (pH 8.5) overnight. Serum samples were diluted in sample buffer 1:25. As a detecting antibody, horseradish peroxidaselabeled sheep antimouse Ig (Amersham Pharmacia Biotech, UK) was used at a dilution of 1:1,000. The reaction was developed by tetramethylbenzidine (TMB) substrate solution and stopped by the addition of 1-m H 2 SO 4 .
Statistical analysis
All statistical analyses were made using the MannWhitney rank test. For all cases, results were considered significant if p values were <0.05.
Results
RNeu protein is expressed in cells transfected with plasmid encapsulated virosomes
To evaluate whether plasmid DNA (fDNA) encapsulated in virosomes would result in expression of the cloned gene and induce protein production, we chose a plasmid vector containing a strong promoter (CMV) for optimal expression in mammalian cells and immunostimulatory cytidine-phosphate-guanosine motifs for increased activation of B cells, T cells, and dendritic cells [24] . We engineered a fDNA-Neu ECD plasmid designed to express the extracellular domain of rat Neu (Neu ECD ). Before testing this plasmid as vaccine in vivo, the protein expression in transfected COS cells was evaluated in immunohistochemical analysis. Cells transfected with fDNA-Neu ECD stained strongly when a mouse antibody (Ab) recognizing an extracellular epitope of rNeu (Ab 7.16.4) was used, whereas no expression could be detected in the same cells when a rabbit antibody recognizing an epitope of the intracytoplasmic part of human/ rat Neu was selected (data not shown). To confirm rNeu ECD protein production in cells transfected with plasmid DNA-Neu ECD encapsulated in virosomes (Vir-DNA-Neu ECD ), immunohistochemical staining was performed on cytospins of Vir-DNA-Neu ECD infected COS cells using again the mouse monoclonal antibody 7.16.4 against rat Neu ECD (Fig. 1) . The spontaneous breast tumor cell line NF9006, as control, showed a strong staining with mAb 7.16.4 (Fig. 1a) . COS cells transfected with Vir-DNA-Neu ECD showed a clear staining for Neu ECD protein in the cytoplasm of 20-30% of these cells using the same mAb 7.16.4 (Fig. 1b) . No staining could be detected in COS cells transfected with empty virosomes or Vir-DNA (no insert) when the same antibody was used (Fig. 1c, d ). These results confirmed that cells transfected with plasmid DNA-Neu ECD encapsulated in virosomes were capable of producing the antigen.
Prophylactic vaccination with fDNA-Neu ECD significantly inhibits tumor formation Virosomes have been used as carriers for the introduction of nucleic acid into mammalian cells in vitro [18] . To evaluate whether Vir-DNA-Neu ECD could be used as vaccine and increase rejection of a tumor challenge compared with fDNA-Neu ECD , the following experiments were performed: MMTV/r-Neu and/or FVB/N female mice were vaccinated and boosted with recombinant vaccinia virus encoding Neu ECD (rVVNeu ECD ), with wild-type vaccinia (WT-VV) as negative control, with fDNA (no insert), with fDNA-Neu ECD , or with Vir-DNA-Neu ECD (as described in ''Material and methods''). Two weeks after the boost, mice were challenged with either the syngeneic rNeu + (NF9006) or rNeu À (K635) breast cancer cell lines and assessed for tumor formation at the challenge site. As shown in Table 1 , immunization with fDNA-Neu ECD s.c. protected 11 out of 15 mice from tumor formation (tumor incidence 4/15). The specificity of this protection was confirmed, as fDNA-Neu ECD vaccination did not %lysis ¼ OD ðtarget aloneÞ À OD ðtarget þ effectorsÞ À ðeffectors aloneÞ ½ OD (target alone) protect mice from forming tumors after a challenge with the rNeu À syngeneic breast cancer cell line (K635). In contrast, the immunization with Vir-DNA-Neu ECD resulted in a lack of protection, as 13 mice out of 14 developed tumors with NF9006 breast cancer cells. The injection of Vir-DNA-Neu ECD s.c. or i.p. showed no difference in tumor rejection. None of the rVV-Neu ECD vaccinated mice developed tumors for an observation period more than 2 months, whereas all mice vaccinated with WT-VV and fDNA (no insert), developed tumors at the challenge site. These results indicated that Vir-DNA-Neu ECD seemed incapable of stimulating tumor rejection. 
We then examined whether mice vaccinated with fDNANeu ECD , either free or encapsulated in virosomes (Vir-DNA-Neu ECD ), would generate rNeu-specific CTLs and/or anti-rNeu Ab responses. A syngeneic rNeu-positive IT22 fibroblast cell line was used as target cells in CTL experiments (see ''Material and methods''). IT22-neu expressed significant amounts of cell surface rNeu as monitored by immunofluorescence staining (Fig. 2) . No rNeu expression was detected on IT22 fibroblasts. Also shown in Fig. 2 is the MHC class I and MHC class II staining of the two syngeneic fibroblast cell lines. Both cell lines expressed similar levels of MHC class I and were negative for MHC class II.
Having demonstrated that vaccination and boost induced tumor rejection in fDNA-Neu ECD but not in Vir-DNA-Neu ECD vaccinated mice, rNeu-specific CTLs were analyzed in spleen cells of animals vaccinated either with fDNA-Neu ECD , Vir-DNA-Neu ECD , fDNA (no insert), rVV-Neu ECD , or WT-VV, using a colorimetric assay with XTT. As shown in Fig. 3a , the CTL activity was most effective in mice immunized with rVV-Neu ECD , with a 6-13-fold greater rNeu-specific lytic activity compared with mice vaccinated with WT-VV. Spleen cells from mice immunized with fDNA-Neu ECD also developed rNeuspecific killing in vitro at different effector to target ratios; however, at a reduced percentage level as mice vaccinated with rVV-Neu ECD . In contrast, there were only background levels of specific cell lysis in mice vaccinated with Vir-DNA-Neu ECD , similar to mice vaccinated with fDNA (no insert) and WT-VV.
To determine whether immunization with the abovementioned vaccines would induce a rNeu-specific humoral immune response, sera of vaccinated and boosted mice were collected at days 49-56 after the first vaccination. The presence of anti-rNeu antibodies was assessed by flow cytometry as previously described [23] . As shown in Fig. 3b , sera from mice injected with rVVNeu ECD showed an impressive level of antibody binding (mean = 31.8, SEM=8.9). Similarly, an increase of antibody binding over baseline was noticed in fDNANeu ECD vaccinated mice (mean = 22.3, SEM=11.0). In comparison, mice primed with Vir-DNA-Neu ECD produced no rNeu-specific IgG (mean = 16.3, SEM=5.0) similar to sera from mice immunized with fDNA or WT-VV (both mean = 15.8, SEM=4.2).
Taken together, these results indicated that the difference in tumor rejection between fDNA-Neu ECD and Vir-DNA-Neu ECD correlated with the discrepancy of the induced cellular and humoral immune responses by the two vaccines. NeuECD + CFA showed no significant difference in time to tumor formation compared with empty Vir (p<1.5). As shown in Fig. 4a , all mice developed tumors within 26 days after tumor cell injection, independent of the vaccine used.
We further investigated the progression of tumor volume in mice with different vaccinations. As shown in Fig. 4b , there was no significant difference in the tumor volume 14 days after first detection of tumor formation in mice vaccinated with the different Vir-p NeuECD constructs. The tumor progression and tumor volumes were not different between the groups either vaccinated with the different Vir-p NeuECD , rVV-Neu ECD (two mice Fig. 3 virosomes induced a cellular immune response [14, 25] . To demonstrate whether immunization with different Vir-p NeuECD constructs was capable of inducing rNeuspecific CTL responses, splenocytes were isolated 7 days after booster injection and neu-specific cytotoxic activity was investigated against IT22-neu/IT22 cells. The data depicted in Fig. 5a indicated that mice immunized with Vir-p NeuECD enc or Vir-p NeuECD mem developed equally effective rNeu-specific killing in vitro at different effector to target ratios. Importantly, there was no difference in the CTL activity from that of mice vaccinated with rVV-Neu ECD . In contrast, mice immunized with empty Vir showed only background levels of specific cell lysis. Consistent with the lack of tumor rejection, animals vaccinated with free p NeuECD + CFA showed significantly lower CTL activity.
To examine whether p NeuECD , either in the membrane or encapsulated in virosomes, could also induce anti-rNeu Abs, sera of vaccinated and boosted mice were collected 49-56 days after the first vaccination. The presence of anti-rNeu Abs was assessed by flow cytometry [23] . Whereas high levels of rNeu-specific antibodies were detected in sera from mice injected with rVV-Neu ECD , no rNeu-specific IgG was detected in sera of Vir-p NeuECD primed mice. Since p NeuECD was expressed and produced in E. coli and therefore unglycosylated, the induced Abs may only recognize the protein backbone. Thus, we developed an ELISA using the same unglycosylated p NeuECD coated to plates as was used in the virosomal vaccine constructs. AntirNeu Abs were now detected in sera of animals immunized with Vir-p NeuECD enc, Vir-p NeuECD mem, or a combination of both and free p NeuECD . In contrast, animals vaccinated with rVV-Neu ECD did not develop Abs recognizing the unglycosylated form of p NeuECD in this ELISA. Empty virosomes did not show a rNeuspecific humoral response in either of both systems. Taken together we showed that immunization with Virp NeuECD constructs induced a p NeuECD -specific cytotoxic and humoral immune response that correlated with tumor rejection.
Discussion
HER-2/neu is an antigen currently being evaluated as a target for antitumor immunotherapy. Although HER-2/ neu is constitutively expressed at low levels on different normal adult tissues, humoral and cellular immunity have been shown in patients with HER-2/neu overexpressing tumors [5, 6] . Whereas this immunity is clearly not sufficient to provide patients with protection against malignant tumors, priming or boosting a preexisting immunity may have therapeutic effects [26, 27] . The development of new vaccines targeting HER-2/neu and designed to generate an immune response capable of rejecting cancer is still needed.
The delivery of the full-length HER-2/neu oncogene as a vaccine raises significant safety issues in patient treatment. The cytoplasmic domain of HER-2/neu exhibits a high constitutive tyrosine kinase activity, and overexpression of this oncogene on cells expressing other members of the epidermal growth factor receptor family could trigger the malignant transformation of infected cells [28] . In some cancer patients humoral and/or cellular immune responses against the extracellular part of HER-2/neu have been detected [29] . The relevance of the extracellular domain of HER-2/neu as immunogen was tested in strategies using DNA vaccines [30] [31] [32] . Repeated intramuscular injection of plasmid DNA encoding rNeu ECD provided intermediate levels of protection against a challenge with tumor cells in mice. Although complete protection was not observed with plasmid DNA, no striking difference in tumor rejection was obtained when plasmid vectors encoding the full-length rNeu protein (Neu), the rNeu extracellular and transmembrane (Neu TM ) domain, or the rNeu extracellular (Neu ECD ) domain were used [30] . Our results supported these reports, showing that DNA-Neu ECD could be used as vaccine and induce an effective tumor rejection combined with a humoral and cytotoxic immune response in a preclinical mouse model.
To improve the immune response and direct fDNANeu ECD to the cytoplasma of APCs, we used virosomes as carrier system. Virosomes are reconstituted from influenza virus envelopes and use the same cell receptormediated endocytosis as its viral counterpart [10] . The receptor binding and the membrane fusion activity of influenza virus with endosomes are known to be mediated by the major viral envelope glycoprotein HA [11, 33] . Similar to viral vectors the mildly acidic pH in the lumen of endosomes triggers the fusion of virosomal with endosomal membranes and thus the release of encapsulated material such as DNA, RNA, or proteins into the cytosol of APCs. Therefore, exogenous in virosomes encapsulated antigens may access the MHC class I pathway without the need of de novo protein synthesis [11, 12, 14, 34] . Not all virosomes are likely to fuse with endosomal membranes, and therefore a fraction will become available for the MHC class II pathway. In the current study, we showed that DNA with virosomes as carrier system penetrated cells and induced protein expression in vitro. In contrast to previous reports, where intranasal DNA vaccines associated with virosomes were applied and induced a humoral and CTL response, Vir-DNA-Neu ECD in our model showed neither CTL nor humoral immune responses or tumor rejection [14, 34] . Whether the difference between these reports and our present study was only based on methods of application of the vaccine, on different vaccination strategy (priming by influenza virus), or on a different virosomal carrier system using Escheriagen (E. coli heat-labile toxin) as adjuvant is still an open question. Whereas in vitro 20-30% of the cells transfected with Vir-DNA-Neu ECD expressed the protein, vaccination with Vir-DNA-Neu ECD in vivo failed to induce an immune response and tumor rejection, in contrast to what was observed after administration of fDNA-Neu ECD .
In humans, immunization strategies using peptides or peptide-pulsed dendritic cells have been shown to be effective at priming naive T cells against these peptides and proteins derived from TAAgs; however, these strategies have yet to show clinical efficacy [35] .
For HER-2/neu, several immunodominant peptides have been identified, including a CTL epitope, E75 (spanning amino acids 369-377), that led to the development of a peptide-based vaccine for clinical applications [36] [37] [38] . One of these peptides (E75) was tested in a clinical setting as vaccine and was able to break tolerance and generate an anti-HER-2/neu CTL response in patients [39, 40] . Whereas these T cells easily recognized peptide-pulsed tumor cells, they failed to recognize and lyse HER-2/neu-expressing tumor cells, raising the question whether peptide-based vaccines may induce peptide-specific but not native protein-specific immune responses. Furthermore, drawbacks of synthetic peptides vaccines are their limited application due to the restriction of HLA-A2.1 epitopes in clinical indication, and their lack of standardized methods to immunize patients.
To avoid the restriction of immunodominant epitopes, as well as to generate durable immunity with putative T-helper epitopes, vaccines using the extracellular domain of HER-2/neu protein (p NeuECD ) were investigated. Immunization of rats with human p NeuECD in CFA did elicit an immune response to the rat HER-2/ neu antigen (rNeu) but did not protect against tumor formation of rNeu-expressing tumors [41] . The same lack of antitumor response was seen in mice vaccinated with human p NeuECD using montaide 720 as an immunoadjuvant [42] . Along the same lines, plasmid DNA vaccines encoding for the human extracellular domain of HER-2/neu did induce only a partial or no protection from a challenge with human HER-2-expressing tumors [30, 42] .
Bearing all these concerns in mind, we investigated the potential of virosomes as an improved protein carrier system and immunoadjuvant in cancer vaccines. Commercially available virosomal vaccines (INFLEX-AL V, EPAXAL) have been shown to be very efficacious and safe [43, 44] . The potential of virosomes as delivery system has been demonstrated for nucleic acids and peptide-based vaccines, e.g., for malaria [45] . Recent reports also concluded that synthetic peptide vaccines administrated s.c. with virosomes were able to induce a strong CTL immunity [25] . Therefore virosomes are expected to generate a strong B-cell and Tcell immune response [9] . In this report, we demonstrated that vaccination of mice with p NeuECD + adjuvant showed tumor rejection in only a few animals and almost no CTL activity, even when tested at different concentrations of the protein (data not shown). The immunogenic effect of p NeuECD was significantly increased when the protein antigen was linked to virosomes, either encapsulated as a soluble protein or bound to the virosomal membrane. Our results indicated that virosomes are a highly suitable carrier system for protein antigens, but did not allow any conclusions whether there is a higher efficiency in protein linked to the virosomal membrane versus its encapsulation. However, we did not observed a complete protection from tumor formation with Virp NeuECD . One reason could be the nature of the protein antigen. We used unglycosylated proteins produced by E. coli, that did not correspond to the TAAg presented by the tumor cells. To further improve the vaccine, one could use proteins produced by eucaryotic cells with similar posttranslation modifications. Furthermore, we did not optimize the efficacy of protective immunity by changing the injection regimen. As a last alternative, the route of immunization may further improve our virosomal vaccination. In our study we noticed the strongest tumor rejection when virosomes were injected i.p.
Taken together our results show that virosomes are a highly suitable carrier system for the delivery of proteins into the cytosol of APCs and therefore effectively stimulate a cellular and humoral immune response and tumor rejection. Furthermore, the application of truncated proteins may avoid patient-specific and HLA-restricted peptide vaccines. This model is providing important preclinical data necessary for designing human vaccination trials after primary surgical treatment, either as a primary vaccination or as a boost in combination with other vaccines in a context of an adjuvant treatment plan.
